Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
J Ovarian Res. 2022 Jul 1;15(1):78. doi: 10.1186/s13048-022-01006-z.
Numerous studies have indicated that the level of the Anti-Müllerian hormone (AMH), one of the main markers for the ovarian reserve, does not fluctuate throughout a menstrual cycle, while some studies have rejected this finding. The purpose of this systematic and meta-analysis study is to consensus on all contradictory studies that have measured AMH levels throughout the menstrual cycle and to investigate the exact extent of AMH variation in a cycle.
The protocol for this meta-analysis was registered at PROSPERO before data extraction. Relevant studies were identified by systematic search in PubMed, ScienceDirect, Embase, Cochrane Library, and Google Scholar with no limitation on publication date. Longitudinal studies which have evaluated AMH levels in the follicular and luteal phases of an unstimulated (natural) menstrual cycle in healthy women without endocrinology or ovarian disorders were included. We used the JBI Critical Appraisal Checklist for assessing the quality of studies found eligible for meta-analysis.
A total of 11 studies involving 733 women with regular menstrual cycles were included. The results showed that the AMH level in the follicular phase was significantly higher than in the luteal phase (95% Cl = 0.11 [0.01 to 0.21]; p < 0.05) and it varies about 11.5% from the luteal phase. The analysis of studies which had also examined the ovulatory phase (n = 380) showed that the serum levels of AMH in the ovulatory phase (about 2.02 ng/ml) did not significantly vary compared to follicular (95% Cl = 0.11 [-0.10 to 0.33]; p = 0.30) and luteal (95% Cl = 0.06 [-0.08 to 0.20]; p = 0.43) phases.
According to the results of this study, AMH levels differ between follicular and luteal phases which might be due to ovarian response to the gonadotropins. It seems the phase of AMH measurement needs to be considered for interpretation of the serum AMH test.
许多研究表明,抗缪勒管激素(AMH)水平作为卵巢储备的主要标志物之一,在整个月经周期中并不波动,而一些研究则否定了这一发现。本系统评价和荟萃分析的目的是就整个月经周期测量 AMH 水平的所有相互矛盾的研究达成共识,并研究周期中 AMH 变化的确切程度。
本荟萃分析的方案在数据提取前在 PROSPERO 进行了注册。通过系统检索 PubMed、ScienceDirect、Embase、Cochrane 图书馆和 Google Scholar,在没有出版日期限制的情况下确定了相关研究。纳入了评估健康女性未受刺激(自然)月经周期卵泡期和黄体期 AMH 水平的纵向研究,这些女性无内分泌或卵巢疾病。我们使用 JBI 批判性评估清单评估适合荟萃分析的研究质量。
共纳入 11 项涉及 733 例月经周期规律的女性的研究。结果表明,卵泡期 AMH 水平明显高于黄体期(95%Cl=0.11[0.01 至 0.21];p<0.05),与黄体期相比变化约 11.5%。对还检查了排卵期的研究(n=380)进行分析显示,排卵期 AMH 血清水平(约 2.02ng/ml)与卵泡期(95%Cl=0.11[-0.10 至 0.33];p=0.30)和黄体期(95%Cl=0.06[-0.08 至 0.20];p=0.43)相比无显著差异。
根据本研究结果,AMH 水平在卵泡期和黄体期之间存在差异,这可能是由于卵巢对促性腺激素的反应。似乎需要考虑 AMH 测量的阶段来解释血清 AMH 检测。